557
Participants
Start Date
December 6, 2012
Primary Completion Date
January 9, 2019
Study Completion Date
January 9, 2019
Isoniazid with HUEXC030 and RZE
Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
HRZE
the same as experimental group,without the excipient of HUEXC030 only
Taipei Veterans General Hospital, Taipei
Tri-Service General Hospital, Taipei
Changhua Christian Hospital, Changhua
Changhua Hosiptal Ministry of Health And Welfare, Changhua
Chang Gung Memorial Hospital, ChiaYi, Chiayi City
Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung City
E-DA Hospital, I-Shou University, Kaohsiung City
Kaohsiung Medical University Hospital, Kaohsiung City
Kaohsiung Veterans General Hospital, Kaohsiung City
Chang Gung Memorial Hospital ,Linkou, Linkou District
Taichung Veterans General Hospital, Taichung
Buddhist Tzu Chi General Hospital, Taipei
Cheng Hsin General Hospital, Taipei
National Taiwan University Hospital, Taipei
Taipei City Hospital, Taipei
Taipei Medical University Hospital, Taipei
Taipei Medical University-Shuang Ho Hospital, Taipei
Taipei Wanfang Hospital, Taipei
National Defense Medical Center, Taiwan
OTHER
National Research Program for Biopharmaceuticals, Taiwan
OTHER
Orient Pharma Co., Ltd.
INDUSTRY